- Home
- HOOK vs MCVT Comparison
HOOK vs MCVT Comparison
Compare HOOK & MCVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOOK
- MCVT
- Stock Information
- Founded
- HOOK 2011
- MCVT 2007
- Country
- HOOK United States
- MCVT United States
- Employees
- HOOK N/A
- MCVT N/A
- Industry
- HOOK Biotechnology: Pharmaceutical Preparations
- MCVT Finance Companies
- Sector
- HOOK Health Care
- MCVT Finance
- Exchange
- HOOK Nasdaq
- MCVT Nasdaq
- Market Cap
- HOOK 9.3M
- MCVT 9.3M
- IPO Year
- HOOK 2019
- MCVT N/A
- Fundamental
- Price
- HOOK $1.25
- MCVT $1.84
- Analyst Decision
- HOOK Buy
- MCVT
- Analyst Count
- HOOK 4
- MCVT 0
- Target Price
- HOOK $10.67
- MCVT N/A
- AVG Volume (30 Days)
- HOOK 62.9K
- MCVT 16.2K
- Earning Date
- HOOK 08-07-2025
- MCVT 08-13-2025
- Dividend Yield
- HOOK N/A
- MCVT N/A
- EPS Growth
- HOOK N/A
- MCVT N/A
- EPS
- HOOK N/A
- MCVT 0.19
- Revenue
- HOOK $9,351,000.00
- MCVT $3,246,479.00
- Revenue This Year
- HOOK N/A
- MCVT N/A
- Revenue Next Year
- HOOK N/A
- MCVT N/A
- P/E Ratio
- HOOK N/A
- MCVT $9.81
- Revenue Growth
- HOOK N/A
- MCVT N/A
- 52 Week Low
- HOOK $0.72
- MCVT $1.13
- 52 Week High
- HOOK $6.77
- MCVT $3.88
- Technical
- Relative Strength Index (RSI)
- HOOK 38.94
- MCVT 50.24
- Support Level
- HOOK $1.23
- MCVT $1.77
- Resistance Level
- HOOK $1.30
- MCVT $1.91
- Average True Range (ATR)
- HOOK 0.06
- MCVT 0.08
- MACD
- HOOK -0.03
- MCVT -0.01
- Stochastic Oscillator
- HOOK 5.97
- MCVT 36.11
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.
About MCVT Mill City Ventures III Ltd.
Mill City Ventures III Ltd is a non-bank lender and specialty finance company. The company is engaged in the business of providing short-term specialty finance solutions to private businesses, micro-and small-cap public companies, and high-net-worth individuals. The principal specialty finance solutions that the group provides are high-interest short-term lending arrangements. Typically, these lending arrangements involve obtaining collateral as security for the borrower's repayment of funds, or personal guarantees from the principals or affiliates of the borrower.